Clinical Trials Directory

Trials / Terminated

TerminatedNCT03782168

Plasma Concentration of Biological Markers in Placental Abruption

Status
Terminated
Phase
Study type
Observational
Enrollment
1 (actual)
Sponsor
University of Arkansas · Academic / Other
Sex
Female
Age
18 Years – 45 Years
Healthy volunteers
Not accepted

Summary

This will be a prospective study conducted on women with a suspected/confirmed diagnosis of placental abruption. Maternal blood samples will be taken at various points during the peripartum period. A healthy group of women admitted for delivery will act as a matched control and will have their blood sampled at similar time points. The primary outcome variables will include the total number of micro-particles, the number of micro-particles from each cell line (platelet, placental, endothelial etc.), and protein markers (specifically; placental growth factor (PlGF), soluble fms-like tyrosine kinase-1 (sFLT-1), vascular endothelial growth factor (VEGF), soluble endoglin (sEng)). Secondary outcomes if will examine the correlation between placental micro-particles, biomarkers, and extent of placental abruption.

Detailed description

The purpose of this study is to determine how well maternal serum biomarkers and placental micro-particles (MP) correlate with PA. The sensitivity and specificity of these proteins will be analyzed to further increase our understanding of the pathological mechanisms involved in PA. The knowledge gained from this study has the potential to develop a diagnostic test for PA with the ability to improve outcomes for mother and baby through earlier diagnosis and targeted therapy.

Conditions

Interventions

TypeNameDescription
OTHERThere is no other intervention, only clinical treatment.The purpose of this study is to determine how well maternal serum biomarkers and placental micro-particles (MP) correlate with PA. The sensitivity and specificity of these proteins will be analyzed to further increase our understanding of the pathological mechanisms involved in PA.

Timeline

Start date
2019-01-31
Primary completion
2019-01-31
Completion
2021-08-01
First posted
2018-12-20
Last updated
2024-09-03

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT03782168. Inclusion in this directory is not an endorsement.